In 2022, COVAX’s efforts targeting long-term COVID-19 impact and beyond, transitioned into the “mRNA Technology Transfer Hub Programme”, convened by WHO and its partner Medicines Patent Pool (MPP).

Five Working Groups (WG) are responsible for the design and coordination of the activities required to fulfill the objectives of the mRNA Technology Transfer Hub Programme.

An independent Steering Committee advises the WHO secretariat on aspects of critical importance to the successful accomplishment of the objectives of the mRNA Technology Transfer Hub Programme.

Additionally, an independent Scientific Advisory Committee (mSAC)  comprising experts in mRNA vaccine development provides technical input into the programme.

The mRNA Technology Transfer Hub Programme operates in close cooperation with the Global Training Hub for Biomanufacturing, convened by WHO and the WHO Academy, to align training needs for both hub and spokes (manufacturing, good practices, technology transfer) and training offer.

MPP Logo

Abonnez-vous à notre newsletter

Créé et financé par

Unitaid Logo

Autres financements